A patient with primary immunodeficiency in rural India receives a monthly immunoglobulin infusion derived from plasma collected thousands of miles away. A hemophilia treatment center in Germany switches to a next-generation clotting factor concentrate produced through advanced fractionation.
These scenarios reflect a single underlying reality: plasma-derived therapies remain irreplaceable for hundreds of thousands of patients worldwide, a dynamic explored in depth in BCC Research's analysis of the blood plasma products market. The companies that collect, fractionate, and distribute these products shape both clinical outcomes and market structure.
The blood plasma products market continues to expand as demand rises for immunoglobulins, albumin, coagulation factor concentrates, fresh frozen plasma, and cryoprecipitate. For market participants, the more important question is not simply how large the market becomes, but which companies are building the supply, manufacturing, and distribution capabilities to shape it.
For corporate strategists, investors, and business development teams, understanding which companies occupy critical positions in this supply chain is essential to identifying where value is created and where risk concentrates.
BCC Research tracks this market through its Global Markets for Blood Plasma Products report, providing detailed segmentation, competitive landscape analysis, and forward-looking projections. This article profiles the companies positioned at critical points in the value chain and examines the structural forces shaping competitive dynamics.
Several converging forces are expanding the addressable market for plasma-derived products. Diagnoses of primary immunodeficiency disorders (PIDDs) continue to rise globally as awareness, screening, and diagnostic capabilities improve.
Immunoglobulin therapies, which account for the largest product segment in the market, are also finding expanded use in neurology, rheumatology, and transplant medicine.
An aging global population amplifies demand further. Older adults are more likely to require albumin for critical care, coagulation factors for surgical support, and immunoglobulins for age-related immune conditions.
In emerging economies, improving healthcare infrastructure is connecting more patients with therapies that were previously inaccessible. This is widening the global consumption base.
Plasma collection remains a structural bottleneck. According to Cornell University's Emerging Markets Institute, five countries provide approximately 80% of the world's plasma supply, with the United States alone contributing roughly 70% of plasma used worldwide. This concentration creates vulnerability. Any disruption to donor participation, regulatory policy, or logistics in a single geography can ripple through the global supply chain.
To mitigate this, manufacturers are investing in collection infrastructure, automated donation systems, and yield-enhancement technologies. The broader strategic goal is clear: improve throughput, protect supply continuity, and increase the therapeutic yield from every liter of collected plasma.
Fractionation technology is advancing in parallel. Next-generation virus-removal filters and high-concentration immunoglobulin formulations enable producers to extract more therapeutic value from each liter of plasma collected.
Vertical integration has become the dominant competitive strategy in the plasma fractionation space.
Companies that control the full chain from donor recruitment through fractionation to finished product distribution hold structural advantages in cost management, supply continuity, and regulatory compliance.
The companies profiled below were selected based on their roles across the plasma-derived therapies value chain: collection, fractionation, product development, and regional distribution. The list reflects the company set identified in the source materials for this article and is organized to show geographic and strategic breadth across the market.
It reflects a cross-section of established multinationals, regional specialists, and growth-stage companies actively influencing market dynamics. The list is organized to represent geographic and strategic diversity rather than rank-order market share.
Headquartered in Melbourne, Australia, CSL operates one of the largest plasma collection networks globally through CSL Plasma, with hundreds of centers concentrated in the United States and expanding into Europe and China.
CSL Behring, the company's biotherapies division, produces immunoglobulins, albumin, and coagulation factors distributed in more than 100 countries. Its investment in automated collection technology and yield-optimization manufacturing positions it as a reference point for operational scale.
Barcelona-based Grifols operates approximately 400 plasma collection centers worldwide and processes an estimated 25% of the global plasma supply.
The company's Bioscience division produces a portfolio spanning immunoglobulins, albumin, alpha-1 antitrypsin, and coagulation factors. Grifols has invested in expanding fractionation capacity and maintaining a large donor network presence in the United States, where much of the world's plasma supply is collected.
Takeda's plasma-derived therapies division, anchored by its BioLife Plasma Services collection network, gives the Japan-based multinational significant upstream control.
The company's portfolio includes immunoglobulin products, albumin, and specialty therapies for rare bleeding and neurological disorders. Takeda has positioned plasma-derived therapies as a long-term strategic pillar with ongoing investments in manufacturing processes and expanded collection capacity.
Privately held and headquartered in Lachen, Switzerland, Octapharma operates its own plasma collection and fractionation infrastructure across Europe and the United States. The company produces immunoglobulins, coagulation factors, and albumin.
Octapharma's private ownership structure has allowed it to reinvest consistently in manufacturing capacity. It has expanded its presence in markets where other producers have limited reach.
Italy-headquartered Kedrion expanded its profile in plasma-derived therapies through its combination with Bio Products Laboratory (BPL), broadening its geographic reach and strengthening its position across collection, fractionation, and distribution.
Kedrion & BPL operates across collection, fractionation, and distribution, with a particularly strong footprint in Europe, the U.K., and the United States.
Based in New Jersey, ADMA Biologics is a vertically integrated, U.S.-based specialty biopharmaceutical company focused on plasma-derived biologics. Its lead product, ASCENIV, is a specialty immune globulin indicated for primary immunodeficiency disease.
ADMA's recent growth underscores how specialty positioning can matter in a market often dominated by scale. Its focus on differentiated immune globulin products illustrates how smaller players can build relevance through narrower therapeutic emphasis rather than broad portfolio breadth alone.
Shanghai RAAS is one of China's largest plasma-derived products manufacturers, operating an extensive network of plasma collection stations domestically. The company produces albumin, immunoglobulins, and coagulation factors primarily for the Chinese market.
Rising healthcare expenditure and expanded insurance coverage in China are accelerating demand. Shanghai RAAS represents the broader trend of Chinese manufacturers building domestic self-sufficiency in plasma-derived therapies to reduce reliance on imports.
South Korea's GC Biopharma operates plasma fractionation facilities domestically and has expanded internationally through technology transfer agreements. In 2025, the company signed a memorandum of understanding with the Thai Red Cross Society to collaborate on workforce training for plasma-derived medicinal product manufacturing.
This reflects GC Biopharma's strategy of building regional production partnerships across Asia. The company's portfolio includes immunoglobulins, albumin, and antihemophilic factor products.
LFB is a French biopharmaceutical company specializing in plasma-derived medicinal products and recombinant proteins. The company is distinct in this market as a state-backed entity, with the French government maintaining significant ownership.
LFB's product portfolio covers immunoglobulins, coagulation factors, and albumin. The company has invested in expanding manufacturing capacity to serve both domestic and international markets.
Part of South Korea's SK Group, SK Plasma operates plasma fractionation facilities and collection infrastructure in the domestic market. The company produces immunoglobulin and albumin products and has been expanding its fractionation capacity. SK Plasma represents the growing role of South Korean companies in the Asia-Pacific plasma-derived therapies supply chain.
Beyond these ten, several other organizations are shaping specific segments or geographies within the blood plasma products market:
Emerging companies such as Prothya Biosolutions (Netherlands), Cytobiologics (U.S.), and Nojin Zist Pharmed Co. (Iran) illustrate the expanding geographic reach of plasma product manufacturing and the market's attractiveness to new entrants pursuing regional or niche strategies.
Examining these companies collectively reveals several structural trends shaping the blood plasma products market:
Vertical integration is accelerating. The most competitively positioned companies control their plasma supply through proprietary collection networks. This upstream control is a direct response to the geographic concentration of plasma sourcing and the risk of supply disruption.
Geographic diversification is a strategic imperative. The dominance of U.S.-sourced plasma creates both opportunity and risk. Chinese manufacturers such as Shanghai RAAS are building domestic capacity to reduce import dependency. South Korean players like GC Biopharma and SK Plasma are expanding regionally through technology transfer.
European companies including LFB and Octapharma are strengthening continental supply chains. These moves reflect a global recalibration of plasma sourcing strategy.
Specialty and differentiated products are commanding growth premiums. ADMA Biologics' ASCENIV, which targets patients who have not responded to standard immunoglobulin therapy, demonstrates that specialty positioning within the immunoglobulin segment can drive outsized revenue growth. This pattern is likely to intensify as manufacturers pursue indication-specific formulations and hyperimmune products.
Technology is redefining manufacturing economics. Yield-enhancement processes, automated collection systems, and advanced fractionation techniques are enabling producers to extract more therapeutic value per liter of plasma.
These innovations directly affect unit economics and competitive positioning, particularly for mid-size manufacturers competing against larger, vertically integrated players.
The companies and trends profiled here provide a structured starting point, but strategic decisions in this market require deeper quantification. Company-level revenue breakdowns, regional segmentation, product-line forecasts, and regulatory mapping are the foundation of informed positioning.
BCC Research's Global Markets for Blood Plasma Products report provides this depth, covering the full spectrum of plasma-derived products, regional dynamics, regulatory factors, and competitive positioning across the companies shaping this market. The report equips corporate strategists, investors, and business development teams with the data infrastructure needed to evaluate opportunities and risks in one of healthcare's most structurally significant supply chains.